Description

Drug Classification:

Flupenthixol + Melitracen Tablets belong to the class of drugs known as antidepressants. This combination medication combines flupenthixol, a neuroleptic agent with antidepressant properties, and melitracen, a tricyclic antidepressant, to provide synergistic effects in the treatment of depression.

Formulations:

• Flupenthixol + Melitracen Tablets:
  • Strength: Each tablet contains Flupentixol 0.5mg and Melitracen 10 mg.
  • Product Form: Oral tablets for convenient administration.
  • Packing Specs: Each pack contains 100 tablets.

Indications:

Flupenthixol + Melitracen Tablets are indicated for the treatment of depressive disorders, including:

• Major Depressive Disorder (MDD): Flupenthixol + Melitracen Tablets are effective in alleviating symptoms associated with major depression, including depressed mood, loss of interest or pleasure, changes in appetite or weight, sleep disturbances, psychomotor agitation or retardation, fatigue, feelings of worthlessness or guilt, and impaired concentration.
• Dysthymia: This medication may also be used in the treatment of dysthymic disorder, a chronic form of depression characterized by persistent low mood and a lack of interest or pleasure in daily activities.

Usage:

• Flupenthixol + Melitracen Tablets should be taken orally with water, preferably with food to minimize gastrointestinal discomfort.
• It is important to adhere to the prescribed dosage and dosing schedule as directed by a healthcare professional.
• Patients should be closely monitored for therapeutic response and any potential adverse effects during treatment.

Dosage:

• The recommended starting dose of Flupenthixol + Melitracen Tablets is one tablet daily.
• Dosage adjustments may be made based on individual patient response and tolerability.
• The maximum recommended daily dose should not exceed two tablets per day.

Pharmacokinetics:

• Flupenthixol and melitracen are both absorbed orally and undergo extensive metabolism in the liver.
• Peak plasma concentrations of both components are typically reached within 2 to 4 hours following oral administration.
• Both drugs exhibit a variable half-life, with elimination primarily via hepatic metabolism and renal excretion of metabolites.

Pharmacodynamics:

• Flupenthixol exerts its therapeutic effects primarily by blocking dopamine D2 receptors in the brain, thereby modulating dopaminergic neurotransmission.
• Melitracen acts as a selective serotonin reuptake inhibitor (SSRI), increasing the concentration of serotonin in the synaptic cleft and enhancing serotonergic neurotransmission.
• The combination of these mechanisms of action results in an improvement in mood and alleviation of depressive symptoms.

Side Effects:

• Common side effects associated with Flupenthixol + Melitracen Tablets may include drowsiness, dizziness, dry mouth, constipation, blurred vision, and weight gain.
• Less common but potentially serious side effects may include extrapyramidal symptoms, orthostatic hypotension, cardiac arrhythmias, and serotonin syndrome.
• Patients should be advised to report any new or worsening symptoms to their healthcare provider promptly.

Trust in the efficacy and safety of Flupenthixol + Melitracen Tablets from AIT Pharmaceuticals Division. Whether you are managing depression or dysthymia, our product offers a reliable solution to help you achieve symptom relief and improve your quality of life. For more information, please visit our website or consult your healthcare provider.